KAZIA THERAPEUTICS LTD
KZIADrugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Lomustine
Glioblastoma
Paxalisib (GDC-0084)
Glioblastoma, Adult
Abemaciclib
CDK Gene Mutation
Opdualag
Childhood Cancer
PAXALISIB
Primary Central Nervous System Lymphoma
Temozolomide capsule
Malignant Primary Gliomas
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lomustine | Phase 3 | Glioblastoma | - | - |
Paxalisib (GDC-0084) | Phase 2 | Glioblastoma, Adult | - | - |
Abemaciclib | Phase 2 | CDK Gene Mutation | - | - |
Opdualag | Phase 2 | Childhood Cancer | - | - |
PAXALISIB | Phase 2 | Primary Central Nervous System Lymphoma | - | - |
Temozolomide capsule | Phase 2 | Malignant Primary Gliomas | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in KAZIA THERAPEUTICS LTD's drug pipeline?→
CatalystAlert tracks 6 drug candidates in KAZIA THERAPEUTICS LTD's (KZIA) pipeline across Phase 3, Phase 2. Its lead program is Lomustine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KAZIA THERAPEUTICS LTD's next FDA catalyst?→
KAZIA THERAPEUTICS LTD's (KZIA) next tracked catalyst is a Phase 2 expected October 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KZIA biotech catalysts?→
Add KZIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KAZIA THERAPEUTICS LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.